EDINBURGH, Scotland, Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.
Management intends to provide a brief update on the Company's operations, clinical trials as well as insight on the company's 2024 outlook and discuss business development efforts. The Company intends to provide a forum for Q&A after remarks by CEO Bryan Kobel.
Conference Call Information:
Date: | Tuesday, March 05, 2024 |
Time: | 4:30 p.m. Eastern Time |
Live Call: | 1-877-704-4453 (U.S. Toll-Free) or 1-201-389-0920 (International) |
|
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
| Last Trade: | US$0.50 |
| Daily Volume: | 0 |
| Market Cap: | US$4.110M |
March 05, 2025 February 13, 2025 February 10, 2025 January 15, 2025 January 13, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
